Testing brentuximab with standard chemo for early Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16–69 years old (and newly diagnosed with classical Hodgkin lymphoma confirmed by biopsy)
- Your lymphoma is stage I or II and located above the belly (no bulky chest tumor and no B symptoms)
- You have not had any Hodgkin lymphoma treatment before (except short steroid pills for up to 7 days)
- Your health tests are good enough for chemotherapy: heart, kidneys, liver, blood counts, and bone marrow
- You are able to follow the study plan, including required birth control if applicable, and you can consent to participate
- Your baseline PET scan shows disease (it must have FDG-avid lesions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug brentuximab vedotin with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) for adults with Stage 3 or 4 Hodgkin lymphoma who have not had previous treatment. It aims to see if this combination works well and is safe.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.